ANI Strikes Deal With Coeptis For Seven Development-Stage Assets

 
• By Penelope MacRae

Continuing its acquisition streak, ANI Pharmaceuticals has bought a pipeline of seven development-stage generics from Coeptis Pharmaceuticals for $2.3m in cash and up to $12m in development and commercial milestone payments.

Slots_777
ANI’s deal for seven generics has fallen into place • Source: Shutterstock

More from Deals

More from Business